Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Simulations Plus, Inc. (NASDAQ:SLP) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $26.50.

Several analysts have recently weighed in on the stock. BTIG Research reduced their price objective on shares of Simulations Plus from $41.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, July 7th. Wall Street Zen upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a research report on Monday, April 28th. Craig Hallum reduced their price objective on shares of Simulations Plus from $45.00 to $36.00 and set a “buy” rating for the company in a research report on Friday, June 13th. Zacks Research upgraded shares of Simulations Plus to a “hold” rating in a research report on Tuesday, August 12th. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Tuesday, July 15th.

Institutional Trading of Simulations Plus

Several institutional investors and hedge funds have recently bought and sold shares of the business. Conestoga Capital Advisors LLC raised its position in Simulations Plus by 17.2% in the 1st quarter. Conestoga Capital Advisors LLC now owns 2,609,388 shares of the technology company’s stock valued at $63,982,000 after purchasing an additional 383,126 shares during the last quarter. Ameriprise Financial Inc. raised its position in Simulations Plus by 25.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock valued at $15,277,000 after purchasing an additional 176,747 shares during the last quarter. Janus Henderson Group PLC raised its position in Simulations Plus by 7,753.3% in the 4th quarter. Janus Henderson Group PLC now owns 542,899 shares of the technology company’s stock valued at $15,141,000 after purchasing an additional 535,986 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Simulations Plus by 6.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 419,241 shares of the technology company’s stock valued at $11,693,000 after purchasing an additional 24,266 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Simulations Plus by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 397,851 shares of the technology company’s stock valued at $6,943,000 after purchasing an additional 12,003 shares during the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Stock Down 2.7%

NASDAQ SLP opened at $14.06 on Wednesday. Simulations Plus has a 52 week low of $12.39 and a 52 week high of $37.72. The stock has a market capitalization of $283.03 million, a PE ratio of -4.46 and a beta of 0.76. The firm has a 50 day moving average of $15.70 and a two-hundred day moving average of $25.22.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Monday, July 14th. The technology company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.19. The business had revenue of $20.36 million during the quarter, compared to the consensus estimate of $22.83 million. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 11.62%. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.27 EPS. On average, equities research analysts expect that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.